Ítem
Acceso Abierto

Respiratory medication used in COPD patients from seven Latin American countries : The lassyc study

Mostrar el registro sencillo de la publicación
dc.creatorCasas, Alejandro
dc.creatorMontes de Oca, Maria
dc.creatorMenezes, Ana MB
dc.creatorWehrmeister, Fernando C
dc.creatorLopez Varela, Maria Victorina
dc.creatorMendoza, Laura
dc.creatorRamírez, Larissa
dc.creatorMiravitlles, Marc
dc.creator.googleCasas, Alejandro
dc.creator.googleMontes de Oca, Maria
dc.creator.googleMenezes, Ana MB
dc.creator.googleWehrmeister, Fernando C
dc.creator.googleLopez Varela, Maria Victorina
dc.creator.googleMendoza, Laura
dc.creator.googleRamírez, Larissa
dc.creator.googleMiravitlles, Marc
dc.date.accessioned2019-09-24T16:43:26Z
dc.date.available2019-09-24T16:43:26Z
dc.date.created2018
dc.date.issued2018
dc.description.abstractBackground: Limited information is available regarding medication use in COPD patients from Latin America. This study evaluated the type of medication used and the adherence to different inhaled treatments in stable COPD patients from the Latin American region. Methods: This was an observational, cross-sectional, multinational, and multicenter study in COPD patients attended by specialist doctors from seven Latin American countries. Adherence to inhaled therapy was assessed using the Test of Adherence to Inhalers (TAI) questionnaire. The type of medication was assessed as: short-acting β-agonist (SABA) or short-acting muscarinic antagonist (SAMA) only, long-acting muscarinic antagonist (LAMA), long-acting β-agonist (LABA), LABA/LAMA, inhaled corticosteroid (ICS), ICS/LABA, ICS/LAMA/LABA, or other. Results: In total, 795 patients were included (59.6% male), with a mean age of 69.5±8.7 years and post-bronchodilator FEV1of 50.0%±18.6%. The ICS/LAMA/LABA (32.9%) and ICS/LABA (27.7%) combinations were the most common medications used, followed by LABA/LAMA (11.3%), SABA or SAMA (7.9%), LABA (6.4%), LAMA (5.8%), and ICS (4.3%). The types of medication most commonly used in each Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013 category were ICS/LABA (A: 32.7%; B: 19.8%; C: 25.7%; D: 28.2%) and ICS/LAMA/LABA (A: 17.3%; B: 30.2%; C: 33%; D: 41.1%). The use of long-acting bronchodilators showed the highest adherence (good or high adherence >50%) according to the TAI questionnaire. Conclusion: COPD management in specialist practice in Latin America does not follow the current guideline recommendations and there is an overuse of ICSs in patients with COPD from this region. Treatment regimens including the use of long-acting bronchodilators are associated with the highest adherence. © 2018 Casas et al.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doi10.2147/COPD.S154097
dc.identifier.issn1176-9106
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/20328
dc.language.isoengspa
dc.relation.citationEndPage1556
dc.relation.citationStartPage1545
dc.relation.citationTitleInternational Journal of COPD
dc.relation.citationVolumeVol. 13
dc.relation.ispartofInternational Journal of COPD, ISSN:1176-9106, Vol. 13 (2018) pp. 1545-1556spa
dc.relation.urihttps://www.dovepress.com/respiratory-medication-used-in-copd-patients-from-seven-latin-american-peer-reviewed-article-COPDspa
dc.rights.accesRightsinfo:eu-repo/semantics/openAccess
dc.rights.accesoAbierto (Texto Completo)spa
dc.source.bibliographicCitationVogelmeier, C.F., Criner, G.J., Martinez, F.J., Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary (2017) Am J Respir Crit Care Med, 195 (5), pp. 557-582spa
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subjectBeta Adrenergic Receptor Stimulating Agentspa
dc.subjectCorticosteroidspa
dc.subjectLong Acting Drugspa
dc.subjectMuscarinic Receptor Blocking Agentspa
dc.subjectRespiratory Tract Agentspa
dc.subjectShort Acting Drugspa
dc.subjectBeta 2 Adrenergic Receptor Stimulating Agentspa
dc.subjectBronchodilating Agentspa
dc.subjectCorticosteroidspa
dc.subjectMuscarinic Receptor Blocking Agentspa
dc.subjectAgedspa
dc.subjectChronic Obstructive Lung Diseasespa
dc.subjectCombination Drug Therapyspa
dc.subjectCross-Sectional Studyspa
dc.subjectDisease Classificationspa
dc.subjectDrug Usespa
dc.subjectForced Expiratory Volumespa
dc.subjectGlobal Initiative For Chronic Obstructive Lung Diseasespa
dc.subjectHumanspa
dc.subjectMaintenance Therapyspa
dc.subjectMajor Clinical Studyspa
dc.subjectMalespa
dc.subjectMedication Compliancespa
dc.subjectMonotherapyspa
dc.subjectObservational Studyspa
dc.subjectPatient Compliancespa
dc.subjectQuestionnairespa
dc.subjectSouth And Central Americaspa
dc.subjectTest Of Adherence To Inhalers Questionnairespa
dc.subjectChronic Obstructive Lung Diseasespa
dc.subjectClinical Practicespa
dc.subjectClinical Trialspa
dc.subjectDrug Effectspa
dc.subjectDrug Utilization Reviewspa
dc.subjectHealth Care Disparityspa
dc.subjectHealth Care Surveyspa
dc.subjectInhalational Drug Administrationspa
dc.subjectLungspa
dc.subjectMedication Compliancespa
dc.subjectMedication Overusespa
dc.subjectMulticenter Studyspa
dc.subjectNebulizerspa
dc.subjectPathophysiologyspa
dc.subjectPrescriptionspa
dc.subjectTreatment Outcomespa
dc.subjectAdrenal Cortex Hormonesspa
dc.subjectAdrenergic Beta-2 Receptor Agonistsspa
dc.subjectAgedspa
dc.subjectBronchodilator Agentsspa
dc.subjectCross-Sectional Studiesspa
dc.subjectDrug Prescriptionsspa
dc.subjectDrug Therapyspa
dc.subjectDrug Utilization Reviewspa
dc.subjectHealth Care Surveysspa
dc.subjectHealthcare Disparitiesspa
dc.subjectLatin Americaspa
dc.subjectLungspa
dc.subjectMalespa
dc.subjectMedication Adherencespa
dc.subjectMuscarinic Antagonistsspa
dc.subjectNebulizers And Vaporizersspa
dc.subjectPrescription Drug Overusespa
dc.subjectTreatment Outcomespa
dc.subjectCorticosteroidesspa
dc.subjectAgente estimulante beta receptor adrenérgicospa
dc.subjectMedicamentos de acción prolongadaspa
dc.subjectEl bloqueo de los receptores muscarínicos agentespa
dc.subject.ddcFarmacología & terapéuticaspa
dc.subject.keywordCorticosteroidspa
dc.subject.keywordInhalationeng
dc.subject.keywordMuscarinic Receptor Blocking Agentspa
dc.subject.keywordAdultspa
dc.subject.keywordArticlespa
dc.subject.keywordFemalespa
dc.subject.keywordAdministrationeng
dc.subject.keywordFemalespa
dc.subject.keywordHumansspa
dc.subject.keywordPractice Patternseng
dc.subject.keywordPulmonary Diseaseeng
dc.subject.lembCorticosteroidesspa
dc.subject.lembMedicamentos de efecto retardadospa
dc.subject.lembEnfermedad pulmonar obstructiva crónicaspa
dc.titleRespiratory medication used in COPD patients from seven Latin American countries : The lassyc studyspa
dc.typearticleeng
dc.type.hasVersioninfo:eu-repo/semantics/publishedVersion
dc.type.spaArtículospa
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
58.pdf
Tamaño:
949.64 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Artículos